Lakefront Biotherapeutics (LKFT) vs Maravai LifeSciences (MRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Maravai LifeSciences (MRVI) has outperformed Lakefront Biotherapeutics (LKFT) over the past year, gaining 124.5% versus a loss of 14.1%. Over five years, LKFT leads with a -43.9% price change compared with -80.0% for MRVI. Maravai LifeSciences is the larger company by market cap ($2.67 billion vs $1.93 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LKFT | MRVI |
|---|---|---|
| Share price | $29.51 | $7.21 |
| Market cap | $1.93B | $2.67B |
| 1-day change | -1.63% | -2.96% |
| YTD return | -8.26% | +128.62% |
| 1-year return | -14.11% | +124.47% |
| 5-year return | -43.95% | -79.97% |
| P/E ratio (TTM) | 2.81 | — |
| EPS (TTM) | $10.52 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $185.74M |
| Revenue growth (YoY) | — | -28.34% |
| Net income (latest FY) | — | $-130.77M |
| Gross margin | — | 18.30% |
| Operating margin | — | -115.89% |
| Net margin | — | -70.41% |
| 52-week high | $36.24 | $9.42 |
| 52-week low | $25.68 | $2.55 |
| Distance from 52-week high | -18.57% | -23.46% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +2.27% | +8.60% |
| Average volume | 267.27K | 3.33M |
| Shares outstanding | 65.48M | 148.99M |
| Employees | 196 | 415 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRVI has outperformed LKFT by 138.6 percentage points over the past year.
About Lakefront Biotherapeutics
LKFT stock →Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 196 employees
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 415 employees
LKFT vs MRVI FAQ
Which is bigger, Lakefront Biotherapeutics or Maravai LifeSciences?
Maravai LifeSciences (MRVI) is larger, with a market capitalization of $2.67B compared with $1.93B for Lakefront Biotherapeutics (LKFT).
Which stock has performed better over the past year, LKFT or MRVI?
MRVI returned +124.47% over the past 12 months, compared with -14.11% for LKFT (price return, excluding dividends). Past performance does not predict future results.
Are Lakefront Biotherapeutics and Maravai LifeSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.